Replies to post #218742 on $Pistol Pete$, $Mick$ & Friends Stock Picks /news,

[mick]

$ACI THANK YOU

RE;
$ACI Albertsons initiated with an Outperform at Telsey Advisory Group; tgt $26

10:18 AM ET 7/21/20 | Briefing.com
Related Quotes


12:56 PM ET 7/21/20
Symbol Last % Chg
ACI
15.72 0.80%
Real time quote.

. Telsey Advisory Group initiates ACI with an Outperform and price target of $26. Analyst Joseph Feldman said, "Albertsons is in the early stages of a transformation that should drive market share gains, earnings growth, and free cash flow for multiple years. This, combined with the current attractive valuation, offers an opportunity for ACI shares to Outperform. Albertsons should continue to benefit from the structural shift in consumer shopping behavior toward digital, increased at-home consumption, and ongoing consolidation. Sustainable growth also should be driven by transformative initiatives, like enhanced merchandising, renewed focus on loyalty, and new digital and omni-channel capabilities. The plan to leverage data analytics and alternative businesses should provide further upside. These actions are likely to make Albertsons long-term targets-ID sales of 2.25%, EBITDA growth of 3%-5%, lower interest expense, EPS growth of HSD, and total shareholder return (TSR) of double-digits-prove conservative. Importantly, Albertsons has improved its balance sheet, with a reduced leverage ratio, and should generate solid free cash flow. Albertsons, in our view, deserve a higher valuation, more like Kroger and other food retailers, given its transformation and stable outlook. As such, our 12-month price target of $26 is based on applying an EV/EBITDA multiple of ~7x to our adjusted 2021 EBITDA of $3.2B. This implies a P/E multiple of ~17x to our adjusted 2021 EPS estimate of $1.53."

[mick]

$AKTX GOING TO MAKE HUGE MOVE SOON. LIKE PRE-MARKETS ONES DO !!!!!

https://investorshub.advfn.com/Akari-Therapeutics-AKTX-30285/

UPDATED IBOX TOO.

[mick]

$TNXP HUGE BUYING LAST TWO DAYS.

[mick]

$AABB MINING WORTH $0.12 TO $0.24 OR MORE !!!!! $AABB I LIKE DIS READ; AABB - Asia Metals Achieves Strong 2nd Quarter Gold Production And On Track To Exceed $12 Million Annual Gross Profit
8:14 am ET July 21, 2020 (Globe Newswire) Print

Asia Broadband Inc. (OTC : AABB), through its wholly owned subsidiary Asia Metals Inc., announced today that the financial results for the
2 quarter ending June 30, 2020,
will be published in the coming weeks confirming the Company's second highest quarterly gross profit to date,
despite the imposed temporary shutdown due to the Covid-19 outbreak.

Gold production more than doubled in the 1 quarter of 2020, in comparison to the 4 quarter of 2019, due to the higher daily
throughput levels and metals extraction efficiencies achieved with
the new production facilities that began the operational phase-in process early this year.

Additionally, the economies of scale from higher productions levels
and lower energy prices both reduced production costs and added to
the bottom-line gross profits for the 1 and 2 quarters.

Fortunately, the ramp-up of production near the end of the 1 quarter could not be completed and booked by March 31 and was carried over
to the 2 quarter results,
significantly counteracting the financial impact of the mandated government shutdown in April and May.

Prior to the repercussions of the pandemic,
the Company expected to have its highest production and gross profit
to date in the 2 quarter.

Management is now expecting this to be achievable in the 3 quarter.

Based on the preliminary results being finalized for the 2 quarter
of 2020, AABB is updating its annual gross profit budget and is projecting it to exceed $12 million in 2020.

Asia Broadband Inc. (OTC : AABB), through its wholly owned subsidiary Asia Metals Inc., is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The Company utilizes its specific geographic expertise, experience
and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious
and base metals in Guerrero, Mexico, to our client sales networks in Asia.

This vertical integration approach to sales transactions is the unique strength of Asia Broadband and differentiates the Company to its shareholders.

Contact the Company at:

Email: [e-mail]

Website: http://www.asiametalsinc.com

Phone: [phone]

Cervitude Intelligent Relations

Nicholas Coriano

Forward-Looking Statements are contained in this press release within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the Asia Broadband Inc.'s (the "Company") expected current beliefs about the Company's business, which are subject to uncertainty and change.

The operations and results of the Company could materially differ from what is expressed or implied by the statements made above when industry, regulatory, market and competitive circumstances change.

Further information about these risks can be found in the annual and quarterly disclosures the Company has published on the OTC Markets website. The Company is under no obligation to update or alter its forward-looking statements as future circumstances, events and information may change.

__GNW8366DE3E__IMG

[mick]

$ACI doing good.

[mick]

$CAPR CHART *W* FORMATION HUGE BREAKOUT !!!!! LOOKING FOR 8'S OR MORE!!!!!

[-chart]finviz.com/chart.ashx?t=CAPR&ty=c&ta=1&p=d&s=l[/chart]

[mick]

$AABB reading review, outstanding !!!!! revs 1!!!! Gold production more than doubled in the 1st quarter of 2020,
in comparison to the 4th quarter of 2019,
re;
AABB News*$12 Million Revenues*Record High Gold Production

This is good news for AABB:
Quote:

https://www.globenewswire.com/news-release/2020/07/21/2064826/0/en/AABB-Asia-Metals-Achieves-Strong-2nd-Quarter-Gold-Production-And-On-Track-To-Exceed-12-Million-Annual-Gross-Profit.html
AABB - Asia Metals Achieves Strong 2nd Quarter Gold Production And On Track To Exceed $12 Million Annual Gross Profit

LAS VEGAS, July 21, 2020 (GLOBE NEWSWIRE) -- Asia Broadband Inc. (OTC : AABB), through its wholly owned subsidiary Asia Metals Inc.,
announced today that the financial results for the 2nd quarter ending June 30, 2020,
will be published in the coming weeks confirming the Company’s second highest quarterly gross profit to date,
despite the imposed temporary shutdown due to the Covid-19 outbreak.

Gold production more than doubled in the 1st quarter of 2020,
in comparison to the 4th quarter of 2019,
due to the higher daily throughput levels and metals extraction efficiencies achieved with
the new production facilities that began the operational phase-in process early this year.

Additionally, the economies of scale from higher productions levels
and lower energy prices both reduced production costs and added to
the bottom-line gross profits for the 1st and 2nd quarters.

Fortunately, the ramp-up of production near the end of the 1st quarter could not be completed and booked by March 31st and was carried over to the 2nd quarter results,
significantly counteracting the financial impact of the mandated government shutdown in April and May.

Prior to the repercussions of the pandemic, the Company expected to have its highest production and gross profit to date in the 2nd quarter. Management is now expecting this to be achievable in the 3rd quarter.

Based on the preliminary results being finalized for the 2nd quarter of 2020, AABB is updating its annual gross profit budget and is projecting it to exceed $12 million in 2020.

Asia Broadband Inc. (OTC : AABB), through its wholly owned subsidiary Asia Metals Inc., is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The Company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Guerrero, Mexico, to our client sales networks in Asia.

This vertical integration approach to sales transactions is the unique strength of Asia Broadband and differentiates the Company to its shareholders.

Contact the Company at:

Email: [e-mail]
Website: http://www.asiametalsinc.com
Phone: [phone]
Cervitude Intelligent Relations
Nicholas Coriano

Forward-Looking Statements are contained in this press release within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the Asia Broadband Inc.’s (the “Company”) expected current beliefs about the Company’s business, which are subject to uncertainty and change.

The operations and results of the Company could materially differ from what is expressed or implied by the statements made above when industry, regulatory, market and competitive circumstances change.

Further information about these risks can be found in the annual and quarterly disclosures the Company has published on the OTC Markets website. The Company is under no obligation to update or alter its forward-looking statements as future circumstances, events and information may change.

v/r
Sterling


Exit Strategy & Etiquette Thoughts for a Stock
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128822531
I never give investing advice; only my beliefs for risks in a stock.

[mick]

$ACI is going to be big winner for all

[mick]

TSLA Bid: 1,587.00 Ask: 1,588.50 Last: 1,587.50 Chg ($): 19.14 Vol:

[mick]

$TSLA earning a.h. market closes today !!!!!

[stock1ace1]

SLBG @.41 *** Slingerbag.Com
!

[mick]

$ACI GOOD REPORE'

[mick]

Physician from Atlanta says hydroxychloroquine is a safe and effective medicine to treat COVID-19.

He notes the media misinformation, and says “There is a concerted effort to keep the safety and efficacy of hydroxychloroquine away from the American public.”

[mick]

$ACI LIKE THIS ONE

[mick]

$COCP Cocrystal Pharma Highlights Publication By Collaborators Of Positive Data Demonstrating Potent In Vitro Inhibition Against Coronavirus In Science Translational Medicine Journal
8:12 am ET August 4, 2020 (Benzinga) Print
– Cocrystal has two exclusive licenses for the coronavirus protease inhibitors described in the publication –


– Cocrystal is currently further conducting preclinical studies of these coronavirus protease inhibitors (3CL) –

BOTHELL, WA, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.(NASDAQ:COCP), ("Cocrystal" or the "Company"),a clinical stage biotechnologycompany discoveringand developingnovel antiviral therapeutics, today announced the publication of preclinical animal studies of coronavirus antiviral compounds in the renowned medical journal, Science Translational Medicine.

The manuscript titled, "The 3C-like protease inhibitors with potent in-vitro inhibition against SARS-CoV-2 and therapeutic efficacy in MERS-CoV infected mice," was published online in the 3 August 2020 Science Translational Medicine Journal. Authors of the published manuscript were Athri D. Rathnayake, Jian Zheng, Yunjeong Kim, Krishani Dinali Perera, Samantha Mackin, David Meyerholz, Maithri M. Kashipathy, Kevin P. Battaile, Scott Lovell, Stanley Perlman, William C. Groutas, Kyeong-Ok Chang.

Data presented in the publication is included in the Company's two exclusive license agreements with Kansas State University Research Foundation ("KSURF") for new coronavirus antiviral compounds with novel mechanism of action.

"Our license agreement with KSURF has continued to exhibit the potential and broad utility of our platform to address the SARS-CoV-2 virus responsible for the COVID-19 worldwide pandemic. To have this compelling data included in the prestigious publication, Science Translational Medicine, is a testament to the potential of these inhibitors to treat COVID-19. The publication supports the quality and importance of the work performed by the group of co-authors," commented Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal.

Under the license agreements with KSURF, Cocrystal has been granted an exclusive, royalty-bearing right and license to certain antiviral compounds for humans and small molecule therapeutic inhibitors against coronaviruses, picornaviruses and caliciviruses covered by patent rights controlled by KSURF. Cocrystal intends to continue development of these antiviral compounds for coronavirus. These licenses significantly expand and further advance the Company's COVID-19 program by providing more targeted and potent compounds.

"We are incredibly enthusiastic with the positive preclinical data and the solid foundation we believe these inhibitors provide for advancing development of SARS-CoV-2 treatment," added Dr. Sam Lee, President of Cocrystal. "The potent activity and the effectiveness of the mechanism of action demonstrated by these coronavirus protease inhibitors is very encouraging. Of utmost interest was the activity seen from a select number of compounds in the study series which were shown to be effective in vitro against SARS-CoV-2. In addition, we continue applying our proprietary platform technology to further optimize properties of lead molecules and are also exploring multiple routes of administration of these COVID-19 antivirals. These findings bolster our belief in the broad-spectrum capabilities and demonstrated proof-of-concept therapeutic efficacy of these inhibitors against human and animal coronaviruses."

Cocrystal initiated its preclinical studies of COVID-19 inhibitors received from KSURF during Q2 2020. The Company has also recently identified additional inhibitors using its proprietary platform technology and anticipates the selection of its lead preclinical molecule by year end.

About Science Translational Medicine

Science Translational Medicine is a weekly journal devoted to research and issues of strong interest to the translational medicine community. Translational medicine topics suitable for submission include any original research findings, discussions or analyses that move the field closer to the goal of improving human health, or the diagnosis and treatment of disease.

Science Translational Medicinepublishes original, peer-reviewed, science-based research articles that report successful advances toward the goal of improving patients' lives. The editors and an international advisory group of scientists and clinician-scientists as well as other experts holdScience Translational Medicinearticles to the same high-quality standard that is the hallmark of the journal Science.

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

[mick]

$MATN MATEON THERAPEUTICS AND ABIOGENESIS TO INITIATE CLINICAL STUDY TO TEST ARTEMISININ AS A TREATMENT FOR COVID-19 IN INDIA
GlobeNewswire
Mateon Therapeutics, Inc.
,GlobeNewswire•August 4, 2020

https://finance.yahoo.com/news/mateon-therapeutics-abiogenesis-initiate-clinical-110000245.html

Mateon Therapeutics, Inc.
,GlobeNewswire•August 4, 2020
AGOURA HILLS, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-ß therapeutics, will be working together with Abiogenesis to initiate ARTI-19 randomized, controlled, multi-site India clinical study of Artemisinin against COVID-19. This is part of the company’s humanitarian effort to fund the global, multi-country, observational trial to address the pandemic with Artemisinin. Given the known safety profile and the widespread availability of Artemisinin the company anticipates that clinical development of Artemisinin can be accelerated to effectively deal with the current COVID-19 pandemic.

The company is inviting nonprofits such as non-government organizations to participate in this trial if they have the logistics to participate in observational trials and to distribute the Artemisinin in their home countries. The trial is expected to accrue a minimum of 3,000 patients. At present the company is engaged in India, Africa and Latin America.

This study is designed to evaluate the safety, tolerability, and effectiveness of Artemisinin when used in combination with standard of care (SoC) in mild and moderate COVID-19 patients. Artemisinin is an anti-viral agent with demonstrated activity against SARS-CoV-2 in-vitro comparable to remdesivir, however, with higher safety index. By targeting the host protein, TGF-ß, Artemisinin avoids resistance mutations which could render vaccine and/or therapeutics against viral protein(s) ineffective.

Pawan Bhusari, CEO, Abiogenesis, stated: “The COVID-19 pandemic is the greatest health challenge for India where the healthcare system is underserved. Abiogenesis is proud to collaborate with Mateon to develop a possible treatment for this virus.

The discovery of Artemisinin as a potential anti-viral agent is particularly important since this program has the potential to address the pandemic effectively because it is based on a product that is readily available. We are thrilled to support Mateon in India with our domain expertise in clinical research to potentially develop a treatment that could be instrumental in treating patients with COVID-19.”

About Artemisinin

Artemisinin can target multiple viral threats including COVID-19 by suppressing both viral replication and clinical symptoms that arise from viral infection. Viral replication cannot occur without TGF-ß. Artemisinin, purified from a plant Artemisia annua, is able to inhibit TGF-ß activity and is able to neutralize SARS-CoV-2 (COVID-19) in vitro at an EC50 of 0.45 ug/ml (Mateon’s test result at Utah State University), and a Safety Index of 140, which is better than remdesivir and chloroquine. The unpurified herb extract has no anti-viral activity. Artemisinin also has been reported to have antiviral activities against hepatitis B and C viruses, human herpes viruses, HIV-1, influenza virus A, and bovine viral diarrhea virus in the low micromolar range. TGF-ß surge and cytokine storm cannot occur without TGF-ß. Clinical consequences related to the TGF-ß surge, including ARDS and cytokine storm, are suppressed by targeting TGF-ß with Artemisinin. Indeed, TGF-ß knockout mice that are genetically TGF-ß deficient, have been shown to be resistant to the influenza virus. In the clinic, Artemisinin exhibits early efficacy signals against COVID-19. To date, 25 effective cases have been reported, with an average time of negative nucleic acid conversion of 4 days, and a negative conversion rate of 10 days after nucleic acid detection reached 96%. No serious adverse reactions were seen. After treatment, the patient's chest image examination showed that the inflammation in the lungs was relieved and the symptoms were significantly improved. Because it targets a host protein- TGF-ß that plays a pivotal role in ARDS pathophysiology (and not a virus-intrinsic target), Artemisinin does not promote the development of drug-resistant viral mutations.

About Mateon Therapeutics

Mateon was created by the recent reverse merger with Oncotelic which became a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer. OT-101, the lead immuno-oncology drug candidate of Mateon/Oncotelic, is a first-in-class anti-TGF-ßRNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer patients in clinical trial settings. Mateon/Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on pediatric cancer patients. Mateon has rare pediatric designation for DIPG (CA4P) and melanoma (CA4P). For more information, please visit http://www.oncotelic.com and
http://www.mateon.com.

Continue reading
About Abiogenesis Clinpharm

Abiogenesis Clinpharm Private Limited (Abiogenesis) is India based Clinical Research Organization (CRO) headquartered at Hyderabad that provides Clinical Trials services to Pharmaceuticals, Medical Devices, Nutraceuticals and Herbal Products companies.

Initiated by a vibrant group of experienced professionals in the clinical trial domain with proven track record, Abiogenesis has committed to exceeding the needs and expectations of its clients by providing an innovative, professional and high quality services with integrity and reliability. Abiogenesis is capable of delivering the quality work from early proof of concept studies to late phase clinical development including post launch product lifecycle management. We believe that each therapeutic product should go through evaluation in clinical development program with all compliances and this is possible when the organizational value system ensures individual integrity, transparency, respect, productivity and compassion. With an execution level experience in most of Asia Pacific countries and still spreading our wings to other countries, our mission is to build a healthier tomorrow for patients by effectively contributing to clinical trial programs. You can get more information about us at www.abiogenesisclinpharm.com

Mateon's Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may”, “expect”, “anticipate” “hope”, “vision”, “optimism”, “design”, “exciting”, “innovative”, “promising”, “will”, “conviction”, "estimate," "intend," "believe", “quest for a cure of cancer”, “innovation-driven”, “paradigm-shift”, “high scientific merit”, “impact potential” and similar expressions are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company’s product candidates and the potential use of the company’s product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the company’s annual report on Form 10-K filed with the SEC on April 10, 2019 and in the company’s other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise.

Contact Information:
For Mateon Therapeutics, Inc.:
Amit Shah
Email: [e-mail]

[mick]

$SONN wit l.o.i. $500,000 milestone payment up to $40,000,000 + 30% on sales is an outstanding deal i.m.o.

[mick]

$SONN Recent Trades - Last 10 of 4921
Time ET Ex Price Change Volume
12:57:54 Q 3.35 -0.27 14
12:57:45 Q 3.3599 -0.2601 10
12:57:33 Q 3.36 -0.26 60
12:57:33 Q 3.36 -0.26 40
12:57:33 Q 3.36 -0.26 5
12:57:33 Q 3.355 -0.265 100
12:57:33 Q 3.3601 -0.2599 60
12:57:33 Q 3.35 -0.27 100
12:57:33 Q 3.3601 -0.2599 40
12:57:33 Q 3.355 -0.265 100

[mick]

$ACI nice divy

[mick]

$TNXP THANK YOU FOR NEWS ITEM !!!!!

Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder
August 06 2020 - 01:00PM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the initiation of a Phase 2 proof-of-concept study using TNX-102 SL for treatment of alcohol use disorder (AUD). The program in AUD is expected to qualify for the 505(b)(2) pathyway for FDA approval.
“We are excited to have received the FDA's IND clearance to begin clinical trials for TNX-102 SL in AUD,” said Seth Lederman, M.D., Chief Executive Officer of Tonix. “An estimated 36 million adults in the United States have AUD, a chronic relapsing brain disease characterized by compulsive alcohol use, loss of control over alcohol intake, and, very commonly, sleep disturbances which significantly impact cognition, mood and the ability to recover. We believe that by improving sleep quality, the mechanism of action of TNX-102 SL, the rate of successful recovery for people with AUD after detox can be improved.”

About Tonix Pharmaceuticals Holding Corp.

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer and autoimmune diseases. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead vaccine candidate, TNX-1800*, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix expects data from animal studies of TNX-1800 in the fourth quarter of this year. TNX-801*, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox and serves as the vector platform on which TNX-1800 is based. Tonix is also developing TNX-2300*, a second live replicating vaccine candidate for the prevention of COVID-19, but using bovine parainfluenza as the vector. Tonix’s lead CNS candidate, TNX-102 SL**, is in Phase 3 development for the management of fibromyalgia. The Company expects results from an unblinded interim analysis in September 2020 and topline data in the fourth quarter of 2020. TNX-102 SL is also in development for agitation in Alzheimer’s disease and alcohol use disorder (AUD). The agitation in Alzheimer’s disease program is Phase 2 ready with FDA Fast Track designation, and the development program for AUD is now also Phase 2 ready. Tonix‘s programs for treating addiction conditions also include TNX-1300* (T172R/G173Q double-mutant cocaine esterase 200 mg, i.v. solution), which is in Phase 2 development for the treatment of life-threatening cocaine intoxication and has FDA Breakthrough Therapy designation. TNX-601 CR** (tianeptine oxalate controlled-release tablets) is another CNS program, currently in Phase 1 development as a daytime treatment for depression while TNX-1900**, intranasal oxytocin, is in development as a non-addictive treatment for migraine and cranio-facial pain. Tonix’s preclinical pipeline includes TNX-1600** (triple reuptake inhibitor), a new molecular entity being developed as a treatment for PTSD; TNX-1500* (anti-CD154), a monoclonal antibody being developed to prevent and treat organ transplant rejection and autoimmune conditions; and TNX-1700* (rTFF2), a biologic being developed to treat gastric and pancreatic cancers.

*TNX-1800, TNX-801, TNX-2300, TNX-1300, TNX-1500 and TNX-1700 are investigational new biologics and have not been approved for any indication.

**TNX-102 SL, TNX-601 CR, TNX-1600 and TNX-1900 are investigational new drugs and have not been approved for any indication.

This press release and further information about Tonix can be found at http://www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (the “SEC”) on March 24, 2020, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris (corporate)
Tonix Pharmaceuticals
[e-mail]
[phone]

Travis Kruse (media)
Russo Partners
[e-mail]
[phone]

Peter Vozzo (investors)
Westwicke
[e-mail]
[phone]


Primary Logo

[mick]

$ACI IN DARE FOR BIGGIE !!!!!

[mick]

$SRNA I TINK 10 OR MORE BAGGER !!!!! $SRNA Surna Announces Largest Contract in its History
GlobeNewswire
Surna Inc
,GlobeNewswire•August 6, 2020
Announces $2.8 million Sales Contract in July

https://finance.yahoo.com/news/surna-announces-largest-contract-history-131500102.html


WAS $4 AH COUPLE BACK

[mick]

$SRNA TWO YEAR CHART: NASDAQ

[mick]

$ACI WHAT WAS CLOSING PPS ?????

[mick]

$SRNA PIONEERS IN CANNABIS CLIMATES/ILLINOIS[BIG COMPANY PETER]

https://surna.com/
https://groadvisorworldwide.com/cultivation-consulting/
https://groadvisorworldwide.com/illinois/
https://surna.com/controlled-climate-systems/
https://surna.com/products/controls/
https://surna.com/products/biosecurity/
https://surna.com/projects-completed/
https://groadvisorworldwide.com/

https://groadvisorworldwide.com/groadvisor-news/
https://groadvisorworldwide.com/sprung-horticulture-buildings/
https://groadvisorworldwide.com/climate-controls-surna/
https://groadvisorworldwide.com/porta-king-modular-build-outs/
https://groadvisorworldwide.com/vividgro-lighting/
https://groadvisorworldwide.com/innovative-growers-equipment/
https://groadvisorworldwide.com/agrowtek-fertigation-systems/
https://groadvisorworldwide.com/cleanleaf-air-filtration/
https://groadvisorworldwide.com/lighting-controls/

https://groadvisorworldwide.com/fix-existing-growing-pains/
CONTACT US
https://groadvisorworldwide.com/planning-new-cannabis-growing-facility/

[mick]

$AABB SAID VALUATION @ LEAST $0.03 entity has 411.65 M outstanding shares.

ASIA BROADBAND INC currently holds about 1.12 M in cash with (2.02 M) of positive cash flow from operations.

This results in cash-per-share (CPS) ratio of 0.03, which can makes it
an attractive takeover target,

given it will continue generating positive cash flow.

[stock1ace1]

Xela $.56

[mick]

$ACI interesting friday 08-07-2020

[mick]

$SNST HY-IQTM NON-TOXIC FOGGER 99.99% GERM KILLING BACTERIA SPECIES,GERMS,
VIRUSES.

HOMES

OFFICES

HOSPITALS

BIG RETAIL

FARMS

BUSES

AIRLINE

CRUISE SHIPS , ETC.

[mick]

$ACI earnings pps are good.P/E multiple of ~17x to our adjusted 2021 EPS estimate of $1.53."

re;
$ACI Albertsons initiated with an Outperform at Telsey Advisory Group; tgt $26

10:18 AM ET 7/21/20 | Briefing.com
Related Quotes


12:56 PM ET 7/21/20
Symbol Last % Chg
ACI
15.72 0.80%
Real time quote.

. Telsey Advisory Group initiates ACI with an Outperform and price target of $26.

Analyst Joseph Feldman said, "Albertsons is in the early stages of a transformation that should drive market share gains, earnings growth, and free cash flow for multiple years.

This, combined with the current attractive valuation, offers an opportunity for ACI shares to Outperform.

Albertsons should continue to benefit from the structural shift in consumer shopping behavior toward digital, increased at-home consumption, and ongoing consolidation.

Sustainable growth also should be driven by transformative initiatives, like enhanced merchandising,

renewed focus on loyalty, and new digital and omni-channel capabilities. The plan to leverage data analytics and alternative businesses should provide further upside.

These actions are likely to make Albertsons long-term targets-ID sales of 2.25%, EBITDA growth of 3%-5%, lower interest expense,

EPS growth of HSD, and total shareholder return (TSR) of double-digits-prove conservative.

Importantly, Albertsons has improved its balance sheet, with a reduced leverage ratio, and should generate solid free cash flow.

Albertsons, in our view, deserve a higher valuation, more like Kroger and other food retailers, given its transformation and stable outlook.

As such, our 12-month price target of $26 is based on applying an EV/EBITDA multiple of ~7x to our adjusted 2021 EBITDA of $3.2B.

This implies a P/E multiple of ~17x to our adjusted 2021 EPS estimate of $1.53."

[mick]

good morning peter & all have ah nice wkend

[mick]

$TSLA AH WOW WOWZER MOVE BY MUSK $TSLA MUSK SMART TO HOLD PPS 5 FOR 1 FORWARD SPLIT

[Rat Fink]

ERBB – 1st ERBB AGM EZ Weed Machine_to_be_in_Health_4_Life_Dispensary_in_Arizona!!!_https://www.facebook.com/ezweed247/



>>>LOTS OF ADDITIONAL EZ WEED & AMERICAN GREEN/ERBB AGM/SMART VENDING MACHINE INFO BELOW!!!...

PHOTO OF EZ WEEDs LAUREN SMMEE, NFL LINEBACKER_LAMMARR_HOUSTON_+_LINDEL_CREED_ERBB_VENDING_DIVISION!!!

SOURCE: https://ih.advfn.com/stock-market/USOTC/american-green-pk-ERBB/stock-news/82542844/ez-weed-tests-selects-american-greens-erbb-propri


SOURCE: "EZ WEED" LINKEDIN WEBSITE: https://www.linkedin.com/company/ez-weed/


OUTSTANDING THAT MORE & MORE BUSINESSES SELECTING AMERICAN_GREEN_SMART_VENDING_MACHINES!!!

LIKE "EZ WEED" AND "EARTHLY MIST DISPENSARIES" IN OKLAHOMA!!!

ANOTHER BUSINESS EZ_WEED_SELECTS_ERBB_AG_SMART_VENDING_MACHINE_SOLUTION_https://ih.advfn.com/stock-market/USOTC/american-green-pk-ERBB/stock-news/82542844/ez-weed-tests-selects-american-greens-erbb-propri

PR LINK EXCERPT BELOW:

Lindel Creed of American Green (ERBB:OTC) chats with retired NFL Linebacker-turned-venture-capitalist Lamarr Houston and Lauren Smee of EZ Weed when visiting American Green's vending machine facility in Gastonia, NC.

EZ Weed Tests and Selects American Green’s (ERBB:OTC) Proprietary Smart Vending Machine -- the AGM -- to Enhance Their Customers’ Cannabis Businesses

PHOENIX, AZ -- May 27, 2020 -- InvestorsHub NewsWire -- American Green (ERBB:OTC) announced today that EZ WEED has selected and purchased the company’s proprietary smart vending solution -- called the “AGM” -- as their “system of choice” for EZ Weed’s new business venture teaming up with prospective cannabis dispensaries throughout the nation.

EZ Weed is run by Managing Partner, Lauren Smee and backed by retired NFL Linebacker-turned-venture-capitalist, Lamarr Houston. Mr. Houston, who played professionally for the Oakland Raiders and Chicago Bears, recently visited American Green’s AGM facility in Gastonia, NC. According to AGM Division Head, Lindel Creed, “It was obvious to me from the minute they both arrived at the AGM facility, that both Ms. Smee and Mr. Houston knew exactly which machine features they required for their venture and, by the time they left the facility, both were convinced that American Green could provide them.”

EZ WEED expects to purchase and supply the AGM Dispensing Vending Machines following their up-and-coming EZ Weed national launch and have already begun securing their location agreements with some of the top dispensaries in the US. According to Ms. Smee, “Our partnership with American Green is vital in reaching our goal of becoming the first national and mainstream marijuana vending machine provider and service. The automation, humanless sales method, and intelligent vending capabilities of the AGM will allow us to scale for high growth.”

EZ WEED was founded in January 2020. The company came to fruition organically through a love of cannabis and Ms. Smee’s extensive knowledge in launching startups -- with a new twist and groundbreaking sales method in the cannabis industry. The average sales process in a dispensary can be anywhere from 15-45 minutes. With EZ WEED, the entire process, even as a first-time user, is on average 3 to 5 minutes.

Besides the state-of-the-art machines, EZ WEED also provides its dispensary partners with “white glove” customer service as well as completely customizable digital marketing for each American Green AGM vending machine it provides. We do all the work pertaining to custom menus, product display, machine maintenance and a dedicated account manager that remotely keeps track of machine sales and inventory.

According to EZ Weed, serving cannabis users in an efficient manner has proven to be a challenge on a national level. With forward-thinking ideas and the backing of the venture capital firm, League Ventures, EZ WEED stands ready to enhance the sales process for new and seasoned cannabis users all across America. Please visit the websites of these two great companies by clicking on their names above.

American Green looks forward to a great long-term relationship with EZ WEED and believes that their expedient, reduced-human interaction is perfect for our country’s environment for today and years to come.

If you are an experienced vending route operator serving a major market and wish to add a complete line of fully legal CBD products to your existing route, you should contact Mr. Lindel Creed at American Green’s AGM Vending Division located in Gastonia, North Carolina. You can email Lindel at [e-mail] or call him on his direct line at 704-718-3158.

;-)

*****NFL LINEBACKER LAMMAR HOUSTON IN JOINT VENTURE_W/EZ_WEEDs_LAUREN_SMMEE_USING_ERBB_AGMs!!!_https://ih.advfn.com/stock-market/USOTC/american-green-pk-ERBB/stock-news/82542844/ez-weed-tests-selects-american-greens-erbb-propri

EXCERPT FROM LINKED PR BELOW:

EZ Weed is run by Managing Partner, Lauren Smee and backed by retired NFL Linebacker-turned-venture-capitalist, Lamarr Houston. Mr. Houston, who played professionally for the Oakland Raiders and Chicago Bears, recently visited American Green’s AGM facility in Gastonia, NC. According to AGM Division Head, Lindel Creed, “It was obvious to me from the minute they both arrived at the AGM facility, that both Ms. Smee and Mr. Houston knew exactly which machine features they required for their venture[/u] and, by the time they left the facility, both were convinced that American Green could provide them.”

;-)

*****ERBB AGM CUSTOMER LAMMAR HOUSTONs COMPANY_IS_LEAGUE_VENTURES_WHICH_HAS_EZ WEED,_ERBB_AGM SMART VENDING MACHINE CUSTOMER, LISTED AS AN "INVESTMENT" ON THE "LEAGUE VENTURES" WEBSITE!

SOURCE #1: https://www.leagueventure.com/bio

SOURCE #2: https://www.leagueventure.com/investments


;-)

GREAT VIDEO OF SEVERAL ERBB "EZ WEED"-WRAPPED_SMART_VENDING_MACHINES!!!_https://www.youtube.com/watch?time_continue=5&v=RndMB1PFqvE&feature=emb_logo

;-)

OUTSTANDING VIDEO THREE ERBB EZ WEED-WRAPPED_MACHINES_W/_NFL_LINEBACKER_LAMMAR_HOUSTON_&_LINDEL_CREED_AMERICAN GREEN VENDING!!! https://www.youtube.com/watch?v=dYuYdAL0g1A&feature=emb_logo

;-)

FANTASTIC_CNET_VIDEO_OF_AMERICAN_GREEN_SMART_VENDING_MACHINE_WORKING!!!>>>_https://www.youtube.com/watch?v=VDEU2_LbIrc

;-)


SPLENDID UNEDITED FULL DEMO VIDEO SHOWING ERBB_AGM_WORKING_GREAT_FROM_START_TO_FINISH!!!>>>_https://otc.watch/wp-content/uploads/rtMedia/groups/108/2017/05/AGM-Demo-for-Email.mp4

;-)

*****EARTHLY MIST DISPENSARY ERBB AGM IS AVAILABLE_24_HRS_PER_EARTHLY_MIST_TWITTER_WEBSITE!!!!_https://twitter.com/earthlymist?lang=en

IF YOU HAVE ANY CONCERNS/UNBELIEFS ABOUT THE AMERICAN GREEN AGM MACHINE, DROP BY AND SEE IT IN PERSON TO DEFINITIVELY CONFIRM "IN PERSON" YOURSELF IT IS THERE OR JUST EASILY CALL THEM!!!

;-)

****HUGE NEWS!!! EARTHLY MIST DEALS WITH_COVID-19_USING_ERBBs_SMART_VENDING_MACHINES!!!_https://www.otcmarkets.com/stock/ERBB/news/Earthly-Mist-Stores-Deal-With-Covid-19-Restrictions-by-Using-American-Greens-ERBBOTC-Smart-Vending-Kiosks-to-Complete-St?id=261795

EXCERPT BELOW FROM NEW PR LINK:

Earthly Mist Stores Deal With Covid-19 Restrictions by Using American Green’s (ERBB:OTC) Smart Vending Kiosks to Complete Store Purchases Without Need of On-site Human Interaction

PHOENIX, AZ and OKLAHOMA CITY, OK, May 12, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- American Green (ERBB:OTC) announced today that one of its best AGM Smart Vending Machine Kiosk customers, Earthly Mist, has successfully integrated ERBB’s proprietary vending technology (called AGM) so that their retail customers and staff never need to interact together in order to complete a transaction at their stores. As a result, this contact-free transaction keeps all parties safer in our Covid-19 environment.

Earthly Mist, like most companies in the retail sector, found itself in a situation when Covid 19 hit, of having to close its stores unless it found a way to continue to serve its clients without risking the health of its employees and customers. Store management came up with a solution to deploy their American Green AGM kiosks to carry out a complete transaction without any human interaction whatsoever.

According to Earthly Mist Manager, Danelle Pierce, “Since our customers and employees’ safety was our #1 priority, we've used American Green’s vending solution, the AGM, as a way to offer contactless purchases that are compliant within our current Covid-19 environment. American Green’s AGM has been great for our clients that still need to complete purchases, but who are concerned about interacting with the public. By making our products available day and night, essential workers still in the workforce no longer need to rush over to our stores before our stores close. We've let our clients know that even through forced shutdowns due to government restrictions, our popular products will remain available to them for purchase any time of the day or night. Our contact-free solution has greatly relieved consumer and employee anxiety and allowed us to continue to offer access to our products during these uncertain times.”

According to Lindel Creed, American Green’s head of the company’s AGM Division, “Earthly Mist and American Green were forced to become very creative in their business thinking and, as a result, have put the Company’s leading edge technology to optimum use while keeping Earthly Mist’s business operating and their client base stress free. Making high-tech security cameras and two-way communications available to customers arriving at the store, coupled with American Green’s proprietary AGM, Earthly Mist can continue to securely dispense its quality products to customers using the kind of ingenuity that has made our country great.”

When visiting the Earthly Mist Facebook Page one can see a flyer mentioning a possible temporary closure; however, the website and Automatic Dispensing AGM Machines still remain available day and night.

In other news, American Green plans to open up 10 additional major markets to experienced vending operators wishing to sell American Green’s Premium CBD line of products. In addition to the AGM smart vending kiosk, the company is also a leading online supplier of America-made, high quality CBD products which it plans to “marry” to its state-of-the-art AGM machines. For a sampling of American Green’s high quality product offerings, simply click on the company’s online store.

If you are an experienced vending route operator serving a major market and wish to add a complete line of fully legal CBD products to your existing route, you should contact Mr. Lindel Creed at American Green’s AGM Vending Division located in Gastonia, North Carolina. You can email Lindel at [e-mail] or call him on his direct line at 704-718-3158.

;-)

$$$ HAPPY EARTHLY MIST REP "WE THINK AGMs BIOMETRIC_ID_FEATURE_ONE_OF_BEST_IN_INDUSTRY"_$$$_https://finance.yahoo.com/news/earthly-mist-dispensaries-select-american-130010340.html

EXCERPT BELOW FROM LINKED ERBB PR:

PHOENIX, AZ, Dec. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Today American Green (ERBB:OTC) is happy to announce that Earthly Mist of Tulsa Ok has purchased and installed the company’s latest series of American Green smart vending machines for use in their very popular Oklahoma dispensaries.

Earthly Mist representative, LeJuan Williams, points out some of the reasons their expanding company chose American Green AGM Systems over their competitors:

The AGM machine gives our dispensaries the ability to add self-checkout as a convenience to our customers while providing an additional security layer for our stores.

We think AGM’s biometric identification feature is one of the best in the industry and ensures that our customers are qualified for the purchases they choose. Earthly Mist sees this as a key benefit to our dispensaries while utilizing the most accurate process we have seen in actual use anywhere.

American Green’s AGM gives Earthly Mist management the ability to examine and track back-end sales and features a robust, and easy-to-navigate touch screen interface making it a great way to promote Earthly Mist products.

“We are thrilled that Earthly Mist is the first group of stores in our part of the world using AGM’s advanced identification technology to deliver visually pleasing, easy-to-navigate, essential information for our customers operating the AGM to select and check out their products,” said LeJuan Williams of Earthly Mist.

“The AGM allows our dispensary customers to come in and operate the machines as self-service stations where they can browse and educate themselves by receiving information provided at the AGM Kiosk,” concluded Mr. Williams.

The American Green AGM is a self-service kiosk system that allows the sale of age-restricted products.

American Green has been testing its AGM system and has begun rolling them out for use in many different markets. Actual field testing has proved that the AGM is not only effective for age-restricted products, but for just about any product that a company may need to vend - all while performing real-time inventory control and limited, age-restricted access to products.

Pan Pacific International, who is American Green’s technology partner, also sells an age-restricted beverage vendor that can be used for Beer or Wine in special market applications and where permitted by law.

“We have been hard at work learning and making changes to our systems, so that they can be versatile and reliable within many different market sectors,” said Lindel Creed, who is Vice President of American Green’s automatic dispensing systems division.

According to Mr. Creed, “It all started with a machine we called ZaZZZ, our first machine which evolved into the automatic dispensing system now known as the AGM. We have made tremendous strides in our machine’s ongoing development, and we believe we now own the ‘Best in Class’ in Automatic Dispensing System for age or limited-access products.”

Lindel Creed continues, “It has not been an easy or a fast process, but the market requires a system that is truly an age verification system, so we have to be certain that the system cannot be manipulated or allow under-age sales - a process that takes time and in-field, real world studies. We have been testing our system in the CBD markets and are now ready to go into other areas of age-restricted sales,” concludes Mr. Creed.

American Green believes that the AGM process is the best way to ensure that it is providing secure and accurate accountability to ensure that the individual registered in the system is actually the same person using the machine. The AGM uses highly precise vein biometrics to identify the buyer and match them to a verified record originally obtained and encoded by a living human being when the member initially enrolls.

The company believes that American Green’s AGM kiosk is the most responsible way to make sure that its customers are protecting themselves with a system whose integrity of verification is the best in the industry.

;-)

EARTHY MIST AMERICAN GREEN AGMs PURCHASE ARTICLE AT KIOSKMARKETPLACE.COM: https://www.kioskmarketplace.com/news/oklahoma-dispensary-operator-installs-american-green-smart-vending-machines/

;-)

EARTHLY MIST AMERICAN GREEN AGMs PURCHASE ARTICLE AT MMJREPORTER.COM: https://mmjreporter.com/self-checkout-feature-of-american-green-inc-otcmktserbbs-smart-vending-machines-powers-customers-of-earthly-mist-dispensaries-in-oklahoma-40057

;-)

[stock1ace1]

Pete, Apex .72 golden cross any day only 4 mill float 5 mill o/s ;))

[stock1ace1]

Trq .92

[mick]

$ACI ready

[mick]

$SNSS Sunesis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Recent Highlights
Sunesis to Host Conference Call Today at 4:30 PM Eastern Time

http://www.globenewswire.com/news-release/2020/08/11/2076704/0/en/Sunesis-Pharmaceuticals-Reports-Second-Quarter-2020-Financial-Results-and-Recent-Highlights.html

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) --
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the second quarter ended June 30, 2020.

Loss from operations for the three months ended June 30, 2020 was $6.3 million.

As of June 30, 2020, cash, cash equivalents and restricted cash totaled $23.2 million.

Subsequent to the end of the quarter,
the Company raised approximately $12.6 million in net proceeds from
an underwritten public offering of its common stock and repaid its outstanding debt.

“We are committing our resources to the development of our first-in-class PDK-1 inhibitor, SNS-510, as we evaluate the path forward for vecabrutinib.

In addition,
we initiated a review of strategic alternatives to maximize shareholder value that can include in-licensing,
partnering, and
mergers and
acquisitions,”
said Dayton Misfeldt, Interim Chief Executive Officer of Sunesis.

“We also took action to strengthen our financial position by extending our cash runway.

In July, we completed a reduction in workforce to right-size the company,

we raised $12.6 million through a public equity offering and
repaid our outstanding debt with Silicon Valley Bank.

We are now well positioned to execute on our objectives.”

[mick]

$SNSS As of June 30, 2020, cash, cash equivalents and restricted cash totaled $23.2 million.


did ya ever restricted cash ?????

dats why i say cash cow !!!!!

[mick]

$SNSS #2 Sunesis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Recent Highlights
Sunesis to Host Conference Call Today at 4:30 PM Eastern Time

http://www.globenewswire.com/news-release/2020/08/11/2076704/0/en/Sunesis-Pharmaceuticals-Reports-Second-Quarter-2020-Financial-Results-and-Recent-Highlights.html

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) --
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the second quarter ended June 30, 2020.

Loss from operations for the three months ended June 30, 2020 was $6.3 million.

As of June 30, 2020, cash, cash equivalents and restricted cash totaled $23.2 million.

=======================================================

Recent Highlights

Bolstered Balance Sheet with Completion of Public Offering and
Retiring Debt. In July 2020, Sunesis completed an underwritten
public offering of shares of its common stock with net proceeds of approximately $12.6 million.

Also in July, the Company repaid its outstanding debt with Silicon Valley Bank.

Announced Reduction in Workforce to Streamline Resources.

In July, Sunesis announced a reduction in workforce of approximately
30% to right size the organization to achieve its objectives and preserve cash resources.

Announced Review of Strategic Alternatives.

In July, the Company announced plans to review strategic alternatives
to maximize shareholder value that can include asset in-licensing, partnering, and mergers and acquisitions.

There can be no assurance that the strategic review will result in
any transaction or other outcome.

The Company does not currently intend to publicly discuss or disclose further developments of the strategic review unless

and until its Board of Directors has approved a transaction or otherwise determined that further disclosure is appropriate.

Continued program of IND-enabling Activities for its
PDK-1 Inhibitor SNS-510. In June 2020,

Sunesis announced that it will focus its resources on the development
of its first-in-class PDK-1 inhibitor, SNS-510. Preclinical studies
of SNS-510 revealed that CDKN2A-mutated tumors are particularly sensitive to SNS-510.

CDKN2A alterations are common in human cancers and may prove to be useful biomarkers for broad investigation of SNS-510 as a monotherapy and in combination with other anticancer agents.

The Company is currently conducting IND-enabling studies and expects
to present additional preclinical findings at a scientific meeting
later this year.

This follows the Company’s decision to not advance its
non-covalent BTK inhibitor vecabrutinib into the originally planned Phase 2 portion of the Phase 1b/2 trial in adults with BTK inhibitor resistant

relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies.

Vecabrutinib continues to exhibit an excellent safety profile and
showed clinical activity,
although this was insufficient to support advancing to the Phase 2 in BTK inhibitor resistant disease.

One CLL patient experienced a partial remission and several patients had stable disease for over 6 months.
[

[mick]

$SNSS SNSS SECURITY DETAILS[Outstanding Shares 111,393,000 03/04/2020

Share Structure
Market Cap Market Cap
30,711,050
08/19/2020


Authorized Shares
Not Available

Outstanding Shares
111,393,000
03/04/2020

[mick]

$SNSS wit dis kind of cash surplus i am expecting ah buyout offer soon !!!!!

[mick]

$ACI one da best to @

[mick]

good morning, happy saturday & all have ah good one

[mick]

$ADIL $5 target
https://www.tipranks.com/stocks/adil/forecast

[mick]

$ABUS $6 target

https://www.tipranks.com/stocks/abus/forecast

[mick]

good morning 08-24-2020

[mick]

$ACI GOOD MORNING

[mick]

$ACI

RE

$ACI Albertsons initiated with an Outperform at Telsey Advisory Group; tgt $26

10:18 AM ET 7/21/20 | Briefing.com
Related Quotes


12:56 PM ET 7/21/20
Symbol Last % Chg
ACI
15.72 0.80%
Real time quote.

. Telsey Advisory Group initiates ACI with an Outperform and price target of $26. Analyst Joseph Feldman said, "Albertsons is in the early stages of a transformation that should drive market share gains, earnings growth, and free cash flow for multiple years. This, combined with the current attractive valuation, offers an opportunity for ACI shares to Outperform. Albertsons should continue to benefit from the structural shift in consumer shopping behavior toward digital, increased at-home consumption, and ongoing consolidation. Sustainable growth also should be driven by transformative initiatives, like enhanced merchandising, renewed focus on loyalty, and new digital and omni-channel capabilities. The plan to leverage data analytics and alternative businesses should provide further upside. These actions are likely to make Albertsons long-term targets-ID sales of 2.25%, EBITDA growth of 3%-5%, lower interest expense, EPS growth of HSD, and total shareholder return (TSR) of double-digits-prove conservative. Importantly, Albertsons has improved its balance sheet, with a reduced leverage ratio, and should generate solid free cash flow. Albertsons, in our view, deserve a higher valuation, more like Kroger and other food retailers, given its transformation and stable outlook. As such, our 12-month price target of $26 is based on applying an EV/EBITDA multiple of ~7x to our adjusted 2021 EBITDA of $3.2B. This implies a P/E multiple of ~17x to our adjusted 2021 EPS estimate of $1.53."

[mick]

$ABUS $MRNA DOING CONFERENCE EARLY MORNING 08-26-2020 PATENT INFRINGEMENT
WIT ABUS

@ LEAST $8.00 OR MORE
OR
BUYOUT

[mick]

Recent Biotech Buyouts of Publicly Traded Companies

[Added PTI and CGIX reverse-mergers.]


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157835128&txt2find=ABUS

[mick]

$ABUS Jul-27-20 Resumed JMP Securities Mkt Outperform $10 ? $8

[mick]

$ABUS $MRNA Investors in Arbutus Biopharma Corporation ABUS need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 18, 2020 $2.50 Put had some of the highest implied volatility of all equity options today.

What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.

It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off.

However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?
Clearly, options traders are pricing in a big move for Arbutus Biopharma shares,

but what is the fundamental picture for the company? Currently, Arbutus Biopharma is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics industry that ranks in the Bottom 29% of our Zacks Industry Rank.

Over the last 60 days, two analysts have increased their earnings estimates for the current quarter, while one have dropped their estimates.

The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of 22 cents per share to a loss of 20 cents in that period.

Given the way analysts feel about Arbutus Biopharma right now, this huge implied volatility could mean there’s a trade developing.

Oftentimes, options traders look for options with high levels of implied volatility to sell premium.

This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.

Looking to Trade Options?
Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners.

In addition to impressive profit potential, these trades can actually reduce your risk.

Click to see the trades now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Arbutus Biopharma Corporation (ABUS) : Free Stock Analysis Report

https://stocktwits.com/BearShorter1

[mick]

$ACI i like

[mick]

$AEMD 08-27-2020 Aethlon Medical to Present at the LD Micro 500 Virtual Conference
PR Newswire PR Newswire•August 27, 2020

https://finance.yahoo.com/news/aethlon-medical-present-ld-micro-120100544.html

SAN DIEGO, Aug. 27, 2020 /PRNewswire/
-- Aethlon Medical, Inc. (Nasdaq: AEMD),
a medical device technology company focused on developing products
to diagnose and treat life and organ threatening diseases, today announced that CEO, Timothy C. Rodell,

MD, is scheduled to present
to a live audience at the LD Micro 500 virtual investor conference
on Thursday, September 3, 2020 at 11:40 am Pacific Time (2:40 pm ET), and will be available for one-on-one meetings with investors throughout the day on September 3, 2020.

The presentation will be aired live and available for replay at the investor relations section of Aethlon Medical's website at http://www.aethlonmedical.com.

The LD Micro 500 will take place September 1-4 and will feature some of the most prominent companies in the micro-cap world, with 500 companies expected to provide updates.

Register here: https://www.webcaster4.com/Webcast/Page/2019/36840.

Those wishing to listen to the presentation over the phone can dial into 877-407-6180 (domestic calls) or 201-689-8050 (international calls).

Replays of the presentation will be available for three months.
reply can be accessed through https://www.webcaster4.com/Webcast/Page/2019/36840.

About Aethlon and the Hemopurifier®
Aethlon is focused on addressing unmet needs in global health.

The Aethlon Hemopurifier is a clinical- stage immunotherapeutic device designed to combat cancer and life-threatening viral infections.

In cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression.

These tumor derived exosomes also seed the spread of metastases and inhibit the benefit of leading cancer therapies.

The Hemopurifier® is an FDA designated

"Breakthrough Device" related to the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy,

and with cancer types in which exosomes have been shown to participate in the development or severity of the disease cancer.

The Hemopurifier also holds a Breakthrough Device designation related to life-threatening viruses that are not addressed with approved therapies.

Aethlon also owns 80% of Exosome Sciences, Inc.,
which is focused on the discovery of exosomal biomarkers to diagnose
and monitor cancer and neurological disease progression.

Additional information can be found online at

http://www.AethlonMedical.com and

http://www.ExosomeSciences.com.

About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector.

LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

Company Contact:

Jim Frakes, CFO
[e-mail]
858-459-7800 extension 3300

Media Contact:
Tony Russo, Ph.D.
Russo Partners, LLC
[e-mail]
212-845-4251

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
[e-mail]
212-966-3650

Cision
Cision
More
View original content:http://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-the-ld-micro-500-virtual-conference-301119380.html

SOURCE Aethlon Medical, Inc.

[mick]

$AABB#2-news 09-01-2020[bloomberg $3,000 ppo gold]Asia Metals Inc. $4 Million Drill Program Assay Results To Be Released September 1, As Bloomberg’s Bull Market Gold Price Trajectory Could Accelerate To $3,000 An Ounce
GlobeNewswire
Asia Broadband Inc.
,GlobeNewswire•August 27, 2020

https://finance.yahoo.com/news/aabb-asia-metals-inc-4-120000170.html

LAS VEGAS, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Asia Broadband Inc. (OTC : AABB), through its wholly owned subsidiary Asia Metals Inc.,
confirmed today that the fifth and final phase of assay results of the Company’s $4 million Phase II Exploration and Development Program will be published Tuesday,
September 1st, as the Company continues accelerating its mining operations expansion.

AABB is on target to achieve it highest production quarter by the end of September.

The Company is also anticipating gold production to triple in 2020 from its 2019 benchmark due to higher daily throughput levels and metals extraction efficiencies achieved with the new production facilities installed earlier this year.

Furthermore, the recent economic conditions have created strong and unprecedented fundamentals for gold producer equities and increased demand from the investment community.

The economic instability, uncertainty and inflationary effects of the Coronavirus pandemic have launched gold and gold producers into a significant growth phase and increased profit margins.

https://www.kitco.com/news/2020-08-24/Gold-at-3-000-Upward-gold-price-trajectory-to-accelerate-Bloomberg-Intelligence.html

AABB’s drilling campaign began in the third quarter of 2019 and was budgeted for 20,000 (m) targeting areas in extended proximity to the Company’s mine in Guerrero, Mexico,

to further delineate the known historical and new gold vein structures. The Company’s management and technical team have been thrilled with the successful drill results of the Phase II Program in all four phases of assay results published in October and December 2019 and February and May 2020.

The highlights of the Phase II drill results have revealed high grade gold mineralization in multiple holes in each phase published attesting to the mine’s historical production to date.

Some of the most significant gold value intersections from previous drill phase results are 4.1 meters (m) graded at 13.2 grams per ton (g/t),

4.9 meters (m) graded at 12.6 grams per ton (g/t), 5.2 meters (m) graded at 11.6 grams per ton (g/t).

Asia Broadband Inc. (OTC : AABB), through its wholly owned subsidiary Asia Metals Inc.,
is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The Company utilizes its specific geographic expertise, experience
and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious
and base metals in Guerrero, Mexico, to our client sales networks in Asia.

This vertical integration approach to sales transactions is the unique strength of Asia Broadband and differentiates the Company to its shareholders.

Contact the Company at:

Email: [e-mail]
Website: http://www.asiametalsinc.com
Phone: [phone]
Parkin Investor Relations
Kevin Parkin

Forward-Looking Statements are contained in this press release within the meaning of the Private Securities Litigation Reform Act of 1995.

These statements are based on the Asia Broadband Inc.’s (the “Company”) expected current beliefs about the Company’s business, which are subject to uncertainty and change.

The operations and results of the Company could materially differ from what is expressed or implied by the statements made above when industry, regulatory,

market and competitive circumstances change. Further information about these risks can be found in the annual and quarterly disclosures the Company has published on the OTC Markets website.

The Company is under no obligation to update or alter its forward-looking statements as future circumstances, events and information may change.

[mick]

$ARCS CUSTODIANSHIP ACTIVATED active listing on Nevada SOS


Entity Name:
ARCIS RESOURCES CORPORATION
Entity Number:
E0206042008-4
Entity Type:
Domestic Corporation (78)
Entity Status:
Active
Formation Date:
03/27/2008
NV Business ID:
NV20081139163
Termination Date:
Perpetual

Annual Report Due Date:
3/31/2021

#2 $ARCS, These 715,052,612 Unrestricted are only shares trading !!!!! there LESS restricted than
unrestricted !!!!!
Restricted
577,997,202
04/03/2020

'Arcis Resources Corporation (ARCS)'

Outstanding Shares;
1,293,049,814 04/03/2020

Unrestricted 715,052,612
Restricted--- 577,997,202
=========================
----------------1.293,049,814

CUSTODIANSHIP OUT NOW!
https://cdn.discordapp.com/attachments/644599962654605323/692753818693140550/unknown.png

[mick]

$AABB Bid: 0.0116 Ask: 0.012 Last: 0.0117 Chg ($): 0.0072 Vol: 359,019,914

[mick]

$AABB Bid: 0.0116 Ask: 0.012 Last: 0.0117 Chg ($): 0.0072 Vol: 359,019,914

[mick]

$ACI $TRVN $TSLA $BIGC $CSCO $INO $NIO $AABB $ECOR $EWLL $KIN

[mick]

good morning peter & all have ah prayerful day. 08-30-2020

[mick]

$CAPR 09-04-2020 Capricor Therapeutics to Present at The LD 500 Virtual Conference
9:01 am ET August 31, 2020 (Accesswire) Print
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / Capricor Therapeutics ("Capricor") (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, today announced that it will be presenting at the LD 500 investor conference on Friday, September 4 at 9:20 AM ET / 6:20 AM PT. Linda Marbán, Ph.D, Chief Executive Officer, will be presenting to a live virtual audience.

Webcast link: https://www.webcaster4.com/Webcast/Page/2019/36933

Register for the conference here: https://ld500.ldmicro.com/.

"We have been waiting for this moment all year long. Due to COVID, it has been nearly impossible for physical conferences to even take place. I want to show the world that you can still learn, have a great time, and see some of the most unique companies in the capital markets today. All without having to step foot outside. For the first time, LD Micro is accessible to everyone, and we are honored to welcome you to one of the most trusted platforms in the space." stated Chris Lahiji, Founder of LD.

The LD 500 will take place on September 1st through the 4th.

View Capricor's profile here: http://www.ldmicro.com/profile/CAPR.

Profiles powered by LD Micro - News Compliments of Accesswire

About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and COVID-19. Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. We are now developing two potential vaccines for COVID-19 as part of our exosome platform. For more information,
visit http://www.capricor.com and follow the Company on Facebook, Instagram and Twitter.

About LD Micro

Back in 2006, LD Micro began with the sole purpose of being an independent resource to the microcap world.

What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space.

The upcoming "500" in September is the Company's most ambitious project yet, and the first event that is accessible to everyone.

For those interested in attending, please contact David Scher at [e-mail] or visit http://www.ldmicro.com for more information.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings, and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on March 27, 2020 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020 as filed with the Securities and Exchange Commission on August 10, 2020. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.

CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor's exosome-based candidates have been approved for clinical investigation.

For more information, please contact:

Media Contact:Caitlin KasunichKCSA Strategic [e-mail]212.896.1241

Investor Contact:Joyce AllaireLifeSci Advisors, [e-mail]617.435.6602

Company Contact:AJ Bergmann, Chief Financial [e-mail]310.358.3201

SOURCE: Capricor Therapeutics via LD Micro

View source version on accesswire.com: https://www.accesswire.com/603948/Capricor-Therapeutics-to-Present-at-The-LD-500-Virtual-Conference

comtex tracking
COMTEX_370406299/2457/2020-08-31T09:01:10

[mick]

$MRNA as time is going on $MRNA did infringement of $ABUS patents !!!!!

re;
MRNA crooks https://www.fr24news.com/a/2020/08/u-s-government-darpa-investigates-moderna-vaccine-patents.html

Quote:
U.S. government Darpa investigates Moderna vaccine patents
August 30, 2020


The US Department of Defense research arm is investigating patents filed and awarded to Moderna, a US biotech company developing a Covid-19 vaccine, after researchers accused the company of not disclosing government funding as it is required by federal law.

In a report released this week, researchers from Knowledge Ecology International (KEI), a patient advocacy group, said Moderna did not disclose in its vaccine patents that it had received around $ 25 million in grants. of the DoD Defense Advanced Research Projects Agency, or Darpa. , to develop its vaccine technology.

“It appears that all of the past and present Darpa awards at Moderna include accountability for the role of government funding for related inventions,” Darpa spokesperson Jared Adams said in an email response to Financial Times.

“In addition, Darpa actively researches agency awards for Moderna to identify which patents and pending patents, if any, can be associated with Darpa support,” he said.

Mr Adams declined to comment further, saying the investigation is continuing. US federal law required government funding to be disclosed in these circumstances, he noted.

Disclosure of federal funding in patents helps determine how public funds are used and whether royalties are paid to the government, which is increasingly interested in expensive drugs that have been developed at the expense of taxpayers.

KEI has reviewed the 126 patents granted to Moderna as well as 154 patent applications. “Despite evidence that multiple inventions were conceived during Darpa Award-supported research, not a single one of the patents or applications awarded to Moderna discloses US federal government funding,” KEI researcher Luis Gil wrote. Abinader.

Video: Coronavirus: the global vaccine race | Interview with FT
Jamie Love, the director of KEI, said the lack of disclosure was “surprising”, especially since some of the federal grants covered the technology Moderna hoped to exploit in its Covid-19 vaccine.

“The apparent lack of government control was also surprising,” he added. KEI had written to Darpa on Thursday requesting an investigation.

Moderna said she believes she has complied with applicable patent reporting requirements regarding patent filings, including those related to the Darpa program.

Moderna is developing a vaccine with nearly $ 1 billion in support from the US government, primarily the Biomedical Advanced Research and Development Authority at the Department of Health and Human Services.

This vaccine, which uses messenger RNA, or mRNA, technology is said to be among the most expensive against Covid-19.

The FT reported in July that the company had presented its vaccine to potential buyers at a range of around $ 50 to $ 60 per two-dose course. The company said it would cost some of its jabs up to $ 37 a dose and revealed a deal with the United States to supply 100 million doses worth $ 1.5 billion. It is in talks with the EU and Japan on supply agreements.

Some competitors’ vaccine prices are significantly lower, recent supply agreements indicate. The vaccine developed by AstraZeneca and the University of Oxford costs around $ 3 per dose, for example.

Moderna has revealed that it has received government funding in investor deposits with the Securities and Exchange Commission.


My opinions and comments are exactly that. They are not a recommendation to either buy or sell any security.

[mick]

$SONN WASHINGTON (AP) — President Donald Trump on Sunday announced emergency authorization to treat COVID-19 patients with convalescent plasma — a move he called “a breakthrough,” one of his top health officials called “promising” and other health experts said needs more study before it’s celebrated.



The announcement came after White House officials complained there were politically motivated delays by the Food and Drug Administration in approving a vaccine and therapeutics for the disease that has upended Trump’s reelection chances.



On the eve of the Republican National Convention, Trump put himself at the center of the FDA’s announcement of the authorization at a news conference Sunday evening. The authorization makes it easier for some patients to obtain the treatment but is not the same as full FDA approval.



The blood plasma, taken from patients who have recovered from the coronavirus and rich in antibodies, may provide benefits to those battling the disease. But the evidence so far has not been conclusive about whether it works, when to administer it and what dose is needed.



In a letter describing the emergency authorization, the chief scientist for the FDA, Denise Hinton, said: “COVID-19 convalescent plasma should not be considered a new standard of care for the treatment of patients with COVID-19. Additional data will be forthcoming from other analyses and ongoing, well-controlled clinical trials in the coming months.”



But Trump had made clear to aides that he was eager to showcase good news in the battle against the virus, and the timing allowed him to head into his convention with momentum. He and aides billed it as a “major” development and used the White House briefing room to make the announcement.



Trump also displayed some rare discipline in the evening news conference, sticking to his talking points, deferring to the head of the FDA, Stephen Hahn, and only taking three questions from reporters.

[mick]

digital dollar MSFT patent holder
https://secure.caseyresearch.com/?cid=MKT472896&eid=MKT475505&channel=%7Bexternalchannel%7D&assetId=AST142584&page=1

[mick]

$ACI good morning peter & all have great trading tuesday 09-01-2020

[mick]

$AABB report good read. very good grams per ton[8grams to 13.2 grams per ton]


Here is the full report with increased gold production and revenue potential!!!

big time potential.

Here is the full report with increased gold production and revenue potential!!!

AABB - Asia Metals Inc. Assay Results From $4 Million Drilling Program Establish High Grade Gold Mineralization,
As Gold Outlook Remains Strong

Press Release | 09/01/2020

LAS VEGAS, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Asia Broadband Inc. (OTC : AABB), through its wholly owned subsidiary Asia Metals Inc., announced today further results of the Phase II Drill Program conducted in close proximity to the Company’s mine in Guerrero, Mexico.

The fifth and final drilling stage of the Phase II Program was completed in August 2020 on the Company’s concessions in the La Coloradas area and consisted of 7 holes to an average depth of 398 meters (m) and 2,785 (m) in total were drilled.

The results revealed high grade gold mineralization intersections in multiple drill holes and the most significant gold values were 4.4 meters (m) graded at 12.3 grams per ton (g/t), 5.2 meters (m) graded at 10.8 grams per ton (g/t) and 5.7 meters (m) graded at 8.0 grams per ton (g/t).

Asia Metals Inc. - Phase II Drilling Program Data August 2020 - La Coloradas

Hole ID Hole (m) Start (m) End (m) Width (m) AU (g/t) AG (g/t)

LC2020AM-LIV 396 297 306 8.8 7.71 0.94
356 369 12.8 2.69 1.37
LC2020AM-LV 406 252 260 7.34 3.18 1.15
304 310 5.2 10.81 0.89
361 374 12.3 1.47 0.54
LC2020AM-LVI 379 248 254 5.9 3.65 1.26
311 318 6.6 5.92 0.97
LC2020AM-LVII 421 276 282 5.7 8.01 1,13
325 333 7.2 4.24 1.22
381 393 11.6 1.93 0.68
LC2020AM-IVIII 383 - - - IR* IR*
LC2020AM-LIX 412 262 276 13.1 2.25 1.89
309 314 4.4 12.31 1.01
378 384 5.8 2.06 0.95
LC2020AM-LX 388 299 306 6.9 5.12 1.23
347 358 10.5 2.86 1.72

* Please note that the IR in data table above represents an Insignificant Result

The $4M Phase II Exploration and Development Program that began in the third quarter of 2019 is now complete with 48 holes and 21,037 (m) total drilled.

AABB’s management and technical team have been thrilled with the successful drill results of the Phase II Program in all five phases of assay results published.

The highlights of drill results have revealed high grade gold mineralization in multiple holes in each phase published attesting to the mine’s historical production to date.

Some of the most significant gold value intersections fr$AABB report good read. very good grams per ton. big time potential.


Here is the full report with increased gold production and revenue potential!!!om all of the results are 4.1 meters (m) graded at 13.2 grams per ton (g/t), 4.9 meters (m) graded at 12.6 grams per ton (g/t), 4.4 meters (m) graded at 12.3 grams per ton (g/t).

The Company is now planning a series of post-program evaluations to prepare to engage in the mineral resource and reserves report generation process.

As AABB continues accelerating its mining operations expansion in 2020 and the outlook for gold remains strong, the Company is on target to achieve it highest production quarter in Q3.

AABB is also anticipating gold production to triple in 2020 from its 2019 benchmark due to higher daily throughput levels and metals extraction efficiencies achieved with the new production facilities installed earlier this year.

Additionally, the recent economic conditions have created strong and unprecedented fundamentals for gold producer equities and increased demand from the investment community.

The economic instability, uncertainty and inflationary effects of the Coronavirus pandemic have launched gold and gold producers into a significant growth phase and increased profit margins.

[mick]

$SONN reads outstanding imo.

https://www.sonnetbio.com/news-media/press-releases/detail/20/sonnet-announces-new-preclinical-data-for-son-1010

[mick]

$ACI i like

[mick]

good morning & to all ah friendly hump day

[mick]

$ACI hanging in dare my friend

[mick]

happy friday & to all an uptick day. 09-04-2020

[mick]

$GOLD will $3,000 happen 2020 ?????

for sure $2,300
da mick

[mick]

remember labor day wkend, long wkend 09-05-07-2020

[mick]

$ACI interesting happy long wkend

[mick]

$ACI performance hmmm

[mick]

Queen – Bohemian Rhapsody (Donald Trump Cover)

[mick]

$ACI storm brewing

[mick]

[mick]

$TSLA falling knife today !!!!!

[mick]

$TSLA Tesla falls 21%, worst single-day loss in its history
PUBLISHED TUE, SEP 8 20206:32 AM EDTUPDATED 2 HOURS AGO
Ryan Browne
@RYAN_BROWNE_
Jessica Bursztynsky
@JBURSZ

https://www.cnbc.com/2020/09/08/tesla-shares-slump-10percent-in-premarket-trading-after-sp-500-snub.html

Tesla shares tumbled Tuesday, after Elon Musk’s electric vehicle maker was left out of the S&P 500 by the committee that decides on new additions to the index.

Tesla shares closed down 21.06%, making it the worst one-day loss on record. Tuesday’s drop brought the company’s market valuation to $307.7 billion. The stock has been on a tear this year, having risen around 300%, and the company is now worth more than some of the world’s largest automakers, including Toyota and Volkswagen.

On Friday, the S&P 500 Index Committee decided to add e-commerce site Etsy, automatic test equipment maker Teradyne and pharmaceutical firm Catalent to the S&P 500, but stopped short of including Tesla. Some investors had expected Tesla to be included this quarter, after it reported its fourth consecutive quarter of profitability in July.

Tesla stock dropped more than 7% after hours on Friday following the news. U.S. markets were closed Monday because of Labor Day.

Tesla’s move lower Tuesday also follows a major reversal in the big technology stocks last week, amid fears that valuations had reached unsustainable levels. Japanese tech investment juggernaut SoftBank was reportedly the mystery “Nasdaq whale” that bought billions of dollars in call options in Big Tech names, including Tesla, Amazon, Microsoft and Netflix, potentially driving up valuations. SoftBank declined to comment on the reports.

Tesla split its stock 5-to-1 at the end of last month, a move that saw its value climb significantly in the run-up despite having no fundamental impact on the stock. But it fell a few days later after Baillie Gifford, its largest outside shareholder, cut its stake in the company. Baillie Gifford said the reduction in ownership was merely down to portfolio restrictions.

Tesla said Tuesday it completed its sale of $5 billion in new stock. The firm closed out the sale by Friday, according to a regulatory filing, just three days after announcing plans to sell the additional shares on Sept. 1.

Meanwhile, Nikola — an electric vehicle start-up vying to take on Tesla — revealed on Tuesday that General Motors had agreed to take an 11% stake in the firm. As part of the deal, GM will produce Nikola’s hydrogen fuel cell electric pickup truck, the Badger, by the end of 2022. Shares of Nikola jumped about 29% in premarket trading while GM jumped 6%.

[mick]

$ACI news

[mick]

$ABUS [u09-15-2020 ]Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright 22nd Annual Global Investment Conference
GlobeNewswire
Arbutus Biopharma Corporation
,GlobeNewswire•September 9, 2020

https://finance.yahoo.com/news/arbutus-participate-virtual-fireside-chat-120000430.html

WARMINSTER, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS),

a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection,

as well as therapies to treat coronaviruses (including COVID-19),

today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 10:30 am ET.

Arbutus Fireside Chat Presenters:

William Collier, President and CEO; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer.

A live webcast of the virtual fireside chat can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com or directly at Live Webcast. An archived replay of the webcast will be available on the Company’s website after the conference.

About Arbutus

Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection.

The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit
http://www.arbutusbio.com.

Contact Information

Investors and Media

William H. Collier
President and CEO
Phone: [phone]
Email: [e-mail]

Pam Murphy
Investor Relations Consultant
Phone: [phone]
Email: [e-mail]

[mick]

Leonard Cohen - Hallelujah (Live In London)

Leonard Cohen - Hallelujah (Live In London)